Gastrium DT

Description

Gastrium DT Tablet (Domperidone)

Manufacturer: Micro Labs Ltd. Generic Name: Domperidone

Indications: Gastrium DT Tablet is used to treat a variety of conditions, including:

• Nausea and Vomiting (including that associated with gastroparesis)
• Non-Ulcer Dyspepsia
• Gastritis
• Migraine (for symptomatic relief of nausea and vomiting)
• Lactation (to promote milk production, though its use for this indication should be carefully considered and discussed with a healthcare professional)

Dosage and Administration:

Gastrium DT Tablet should be taken on an empty stomach, preferably 15-30 minutes before meals.

Adults (Oral):

• Nausea and Vomiting: 10-20 mg every 4-8 hours. Maximum dose: 80 mg/day.
• Non-Ulcer Dyspepsia: 10 mg three to four times daily. Maximum dose: 20 mg three to four times daily. The last dose should be taken at bedtime.
• Migraine: 20 mg every 4 hours. Maximum: 4 doses per 24 hours.

Adults (Rectal):

• Nausea and Vomiting: 60 mg twice daily.

Elderly:

• No dosage adjustment is typically needed.

Hepatic Impairment:

• No dosage adjustment is typically needed.

Children (Oral):

• 0.2 – 0.4 mg/kg every 4-8 hours daily.

Children (Rectal):

• <12 years and >15 kg: 30 mg twice daily.
• >12 years and >35 kg: 60 mg twice daily.

Renal Impairment:

• Mild to Moderate: No dosage adjustment is typically needed.
• Severe: Dosing should be reduced to 1-2 times daily with prolonged treatment.

Contraindications:

• Hypersensitivity to domperidone or any component of the formulation.
• Gastrointestinal hemorrhage, mechanical obstruction, or perforation.
• Patients with prolactin-releasing pituitary tumors.
• Chronic administration or routine prophylaxis of postoperative nausea and vomiting.

Precautions:

• Use with caution in patients with pheochromocytoma due to the risk of hypertensive crisis.
• Use with caution in children younger than 2 years.
• Exercise caution in elderly patients and those with renal or hepatic impairment.
• Intravenous administration carries a risk of cardiac arrhythmias and hypokalemia.
• Pregnancy and Lactation: Use during pregnancy and lactation should be carefully considered and discussed with a healthcare professional.

Interactions:

• May antagonize the hypoprolactinemic effect of bromocriptine.
• Opioid analgesics and antimuscarinics may antagonize the prokinetic effect of domperidone.
• Potentially Fatal: Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, ritonavir) may significantly increase serum domperidone levels, raising the risk of QT prolongation and serious cardiac arrhythmias.

Adverse Effects:

• Common: Drowsiness, extrapyramidal reactions, galactorrhea, gynecomastia, constipation or diarrhea, lassitude, decreased libido, skin rash, itching.
• Potentially Fatal/Serious: Convulsions, arrhythmias and cardiac arrest (especially in patients with pre-existing cardiovascular disease or hypokalemia, or those on cancer chemotherapy), seizures, hypertensive crisis (in patients with pheochromocytoma).

Mechanism of Action: Domperidone acts as a peripheral dopamine-receptor blocker. It enhances gastrointestinal motility by increasing esophageal peristalsis, improving gastroduodenal coordination, lowering esophageal sphincter pressure, and facilitating gastric emptying. This leads to a decrease in small bowel transit time.

Important Note: The information provided here for Gastrium DT Tablet is for general knowledge and information purposes only, and does not constitute medical advice, diagnosis, or treatment. It is not intended to be a substitute for the exercise of professional medical judgment. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.